Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer

Damora Therapeutics Inc. (NASDAQ:DMRA) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 23, Damora Therapeutics appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30. Jarrett, who will also join the Board of Directors, previously served as COO and CFO at Arcus Biosciences and held executive roles at Uber and Medivation. Her background in oncology drug development and investment banking is expected to accelerate the development of DMR-001, the company’s lead program for mutant calreticulin-driven blood disorders.

In addition to the new CEO, the company has expanded its Board of Directors with the appointments of Dr. Cameron Turtle and Mike Landsittel. Dr. Turtle currently serves as CEO of Spyre Therapeutics, while Landsittel is the former CFO of Blueprint Medicines. Simultaneously, Peter Harwin, a founding partner at Fairmount Funds Management, has been named Chairman of the Board, succeeding departing directors Dr. Carl Goldfischer, Dr. Jayson Dallas, and Amit Munshi.

These leadership changes follow the recent transaction between Damora and Galecto, signaling a strategic shift toward rapid clinical advancement and commercial readiness. The new team will oversee a portfolio aimed at redefining care for myeloproliferative neoplasms. With a reinforced board and executive leadership, the company plans to leverage its strong balance sheet to advance its pipeline assets and deliver value to shareholders.

Damora Therapeutics Inc. (NASDAQ:DMRA) is a biotech company focused on redefining care for hematologic disorders. The company is advancing a new generation of biologics targeting mutant calreticulin-driven myeloproliferative neoplasms, such as essential thrombocythemia and myelofibrosis.

While we acknowledge the potential of DMRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.